Compare Ascendis Pharma A/S (ASND) vs ON Holding AG (ONON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs ON Holding AG — how do they compare? Ascendis Pharma A/S trades at $263.66 (market cap $17.74B), while ON Holding AG trades at $39.01 (market cap $12.85B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, ON Holding AG nearer its low. Which is the better fit depends on your goals.
| ASND | ONON | |
|---|---|---|
Market Cap | $17.74B | $12.85B |
Sector | Health | Technology |
52-Week High | $277.18 | $54.24 |
52-Week Low | $163.32 | $31.88 |
Enterprise Value | $18.11B | $12.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
ONON trades at $38.54, up 4.81% today, with strong earnings beats in recent quarters. The stock shows bearish technical signals but benefits from robust fundamentals including 63.88% gross margins and 15.5% ROE. Analyst sentiment is overwhelmingly positive with a $47.33 consensus target, though technical indicators suggest near-term resistance at $39.
Outlook remains favorable given consistent earnings outperformance and margin expansion, but elevated valuation multiples and bearish technical trends present near-term risks. The primary opportunity lies in continued execution against growth targets, while risks include market volatility and competitive pressures in the athletic apparel sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About ON Holding AG
ON Holding AG is a Swiss sports company primarily known for its high-performance running shoes, apparel, and accessories under the 'On' brand. The company emphasizes a blend of high-end design, proprietary cloud technology (like CloudTec cushioning), and sustainability in its products. On has rapidly gained market share globally, appealing to both competitive athletes and general consumers in the performance and lifestyle footwear segments.
Read more on ONON →
